Cite
An FDA oncology analysis of immune activating products and first-in-human dose selection.
MLA
Saber, Haleh, et al. “An FDA Oncology Analysis of Immune Activating Products and First-in-Human Dose Selection.” Regulatory Toxicology & Pharmacology: RTP, vol. 81, Nov. 2016, pp. 448–56. EBSCOhost, https://doi.org/10.1016/j.yrtph.2016.10.002.
APA
Saber, H., Gudi, R., Manning, M., Wearne, E., & Leighton, J. K. (2016). An FDA oncology analysis of immune activating products and first-in-human dose selection. Regulatory Toxicology & Pharmacology: RTP, 81, 448–456. https://doi.org/10.1016/j.yrtph.2016.10.002
Chicago
Saber, Haleh, Ramadevi Gudi, Michael Manning, Emily Wearne, and John K. Leighton. 2016. “An FDA Oncology Analysis of Immune Activating Products and First-in-Human Dose Selection.” Regulatory Toxicology & Pharmacology: RTP 81 (November): 448–56. doi:10.1016/j.yrtph.2016.10.002.